No Data
No Data
Natera Is Maintained at Overweight by Piper Sandler
Natera Granted US Patent for Testing Single Nucleotide Variants
Piper Sandler Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $205
Express News | Natera Receives New Patent Related To Testing Of Single Nucleotide Variants In Circulating-Tumor DNA
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
Natera Full Year 2024 Earnings: Beats Expectations